Presepsin and CD64 for Early Sepsis Recognition in Children
Neither presepsin nor neutrophil CD64 are currently recommended by major pediatric sepsis guidelines for routine clinical use in early sepsis recognition, as systematic screening should rely on clinical assessment and validated scoring systems rather than specific biomarkers. The Surviving Sepsis Campaign guidelines for children (2020) recommend implementing systematic screening protocols but do not endorse any specific biomarker for early sepsis detection 1.
Guideline-Based Approach to Early Sepsis Recognition
The current standard for early sepsis recognition in children focuses on:
- Systematic clinical screening using validated protocols tailored to institutional resources and patient populations 1
- Blood cultures obtained before antimicrobial therapy when this doesn't substantially delay treatment 1
- Clinical assessment rather than reliance on single biomarkers for diagnosis
Notably, the Surviving Sepsis Campaign was unable to issue recommendations about using blood lactate values to stratify children with suspected sepsis into risk categories 1, highlighting the limited evidence base for biomarker-driven sepsis recognition in pediatrics.
Research Evidence on Presepsin vs CD64
While guidelines don't endorse these biomarkers, recent research provides comparative insights:
Presepsin Performance
Presepsin shows the highest specificity among novel biomarkers for neonatal early-onset sepsis, with pooled specificity of 0.91 (95% CI: 0.85-0.95) and sensitivity of 0.93 (95% CI: 0.86-0.95) in culture-proven sepsis 2. Key findings include:
- Diagnostic accuracy: In pediatric emergency settings, presepsin levels >2000 pg/mL consistently identified confirmed sepsis cases, while CRP and procalcitonin were less reliable 3
- Bacterial vs viral differentiation: Presepsin distinguished bacterial infections (mean 526 pg/mL) from viral infections (mean 309 pg/mL) with statistical significance (p=0.0398) 3
- Severity correlation: Presepsin at 72 hours showed fair diagnostic accuracy (AUC 0.730) for septic shock, with significantly elevated levels in shock patients (1129.1 ± 1133.80) versus non-shock (472.5 ± 507.81) 4
Neutrophil CD64 Performance
CD64 demonstrates the highest sensitivity for early sepsis diagnosis among single biomarkers studied:
- Diagnostic accuracy: At cutoff 41.6%, nCD64 achieved sensitivity 94.7%, specificity 93.6%, and AUC 0.925 5
- Prognostic value: nCD64 showed significant correlation with sepsis severity and prognosis, with superior monitoring capability (dC Z value -5.904) compared to presepsin (dC Z value -4.494) 5
- Combined with HLA-DR: The sepsis index (ratio of nCD64/mHLA-DR) achieved 88% sensitivity and 86% specificity, with combined use of all three markers approaching 100% sensitivity 6
Comparative Performance
The combination of presepsin and CD64 outperforms either marker alone:
- Combined measurement achieves the highest diagnostic performance in neonatal sepsis 5
- Either CD64 or presepsin combined with high-sensitivity CRP provides better performance than any single marker 5
- CD64 offers superior monitoring and prognostic capability, while presepsin provides better specificity 5
Clinical Application Algorithm
Given the evidence-practice gap, here's a practical approach:
Primary screening: Use systematic clinical protocols with validated scoring systems (not biomarker-dependent) 1
When sepsis is suspected clinically:
If biomarkers are available (research/specialized centers):
- CD64 preferred for: Early diagnosis (highest sensitivity), monitoring treatment response, prognostic assessment
- Presepsin preferred for: Distinguishing bacterial from viral infections (highest specificity), severity stratification after 72 hours
- Combined use: Maximizes diagnostic accuracy when both are available
Critical Caveats
- Do not delay treatment waiting for biomarker results; clinical assessment drives immediate management 1
- Presepsin has limited early diagnostic ability and shows better performance at 72 hours rather than admission 4
- Neither biomarker is standardized for routine clinical use in pediatrics; availability varies significantly between institutions
- Cost-effectiveness remains unproven for routine screening versus targeted use in high-risk populations
- Gestational age and timing affect interpretation, particularly for presepsin in neonates 2
The evidence suggests both biomarkers have research value, but clinical judgment and systematic protocols remain the cornerstone of early sepsis recognition in children, as reflected in current guidelines 7, 1.